Scinai Immunotherapeutics (SCNI) Research & Development (2015 - 2026)

Scinai Immunotherapeutics has disclosed Research & Development across 12 years of filings, most recently posting -$211000.0 for Q2 2026.

• In Q2 2026, Research & Development fell 463.79% year-over-year to -$211000.0; the TTM figure through Jun 2026 stood at -$2.1 million (up 47.85% YoY), while the FY2025 annual figure was -$2.4 million, up 57.18% from the prior year.
• Research & Development came in at -$211000.0 for Q2 2026 at Scinai Immunotherapeutics, up from -$628000.0 in the prior quarter.
• In the past five years, Research & Development ranged from a high of $2.0 million in Q1 2023 to a low of -$4.4 million in Q2 2024.
• Average Research & Development over 5 years is -$9687.5, with a median of -$76500.0 recorded in 2025.
• Year-over-year, Research & Development soared 141.83% in 2022 and slumped 463.79% in 2026.
• Over 5 years, Research & Development stood at $1.4 million in 2022, then slumped by 143.72% to -$627000.0 in 2023, then sank by 113.24% to -$1.3 million in 2024, then jumped by 104.34% to $58000.0 in 2025, then tumbled by 463.79% to -$211000.0 in 2026.
• Per Business Quant data, the three most recent Research & Development figures were -$211000.0 in Q2 2026, -$628000.0 in Q1 2026, and $58000.0 in Q2 2025.